Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2017 March;59(1) > Panminerva Medica 2017 March;59(1):97-106

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Panminerva Medica 2017 March;59(1):97-106

DOI: 10.23736/S0031-0808.16.03228-6

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis

Jing L. REN 1, Hui F. WU 1, Wen J. WANG 2, Gui M. HU 1, Bin GU 1, Min ZHANG 1, Yu X. WANG 1

1 Department of Pathology, the Second Affiliated Hospital, Zhengzhou University, Zhengzhou, China; 2 Department of Thoracic Surgery, the Second Affiliated Hospital, Zhengzhou University, Zhengzhou, China


PDF


INTRODUCTIONː The prognostic value of c-Met in patients with esophageal cancer (EC) remains inconsistent and controversial. Our study aims to clarify the correlation between c-Met overexpression and clinical outcome in EC patients.
EVIDENCE ACQUISITIONː We performed a comprehensive search of EMBASE, PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI) and Chinese Biomedical Database (CBM) (from inception to May 1, 2016) for published literature regarding the potential association between c-Met overexpression and clinical outcome in EC patients. A fixed-effects or random-effects model according to heterogeneity was applied to calculate the pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS), disease-free survival (DFS) and disease-specific survival (DSS).
EVIDENCE SYNTHESISː Nine eligible studies totaling 1062 patients were identified in this meta-analysis. C-Met overexpression was significantly associated with shorter OS (HR: 2.04, 95% CI: 1.66-2.52, P<0.001) and DSS (HR: 3.03, 95% CI: 2.04-4.48, P<0.001) in patients with EC. However, no significant relationship between high expression of c-Met and DFS that was found (HR: 1.81, 95% CI: 0.77-4.26, P=0.176). For OS, similar associations were demonstrated in either esophageal squamous cell carcinoma (ESCC) (HR: 2.17, 95% CI: 1.62-2.90, P<0.001) or esophageal adenocarcinoma (EAC) (HR: 1.92, 95% CI: 1.42-2.59, P<0.001). Additionally, further subgroup analyses according to publication year, ethnicity, the sample size, and statistical methodology all revealed a significant association between high expression of c-Met and OS in patients with EC.
CONCLUSIONSː The current evidence indicated that c-Met overexpression is significantly associated with a poorer prognosis in EC. C-Met may serve as a potential novel prognostic biomarker for EC patients.


KEY WORDS: Esophageal neoplasms - Proto-Oncogene Proteins c-met - Prognosis - Meta-analysis

top of page